Dr. Wade King
Dr. Wade King was appointed CEO of Prota Therapeutics in February, 2019. Wade brings highly successful, senior roles across multiple facets of the health care industry to the company. Previously, Wade was Chief of Anesthesiology for a 20-physician practice in Silicon Valley. During his clinical years Wade became an expert in drug delivery and consulted frequently to the venture capital community regarding early stage health care investments. Following Stanford Business School, Wade went on to become a repeat Wall Street Journal All Star Health Care Analyst and Director of Investment Research for multiple investment banks. Subsequently, Wade was Senior Portfolio Manager and COO at Investment Management firms. Wade then went on to multiple senior operating roles in biotechnology companies. He led both Finance and Business Development for Neomend, a surgical sealant company that was acquired by CR Bard, now part of Becton Dickinson. Subsequently, Wade led Corporate Development and Strategy and served on the management team of Insmed, a multi-billion dollar public rare disease company. While at Insmed, Wade led the exclusive global licensing of a novel DPP1 inhibitor from Astra Zeneca in a deal worth potentially hundreds of millions of dollars. Wade is a board-certified anesthesiologist and completed residencies in Surgery and Anesthesiology at UCSF. Wade holds an M.S.M. from Stanford Business School, M.D. and M.P.H. degrees from UNC Chapel Hill Schools of Medicine and Public Health, and a B.A. cum laude from Princeton University.
Prof. Mimi Tang
Chief Medical & Scientific Officer
Prof Tang is the inventor of the patented combination probiotic food allergen oral immunotherapy technology. She is a paediatric allergist immunologist and researcher at the Royal Children’s Hospital and the Murdoch Children’s Research Institute (MCRI), Australia, with over 25 years clinical experience in pediatric allergy, and 20 years research experience in clinical trials, investigation of immunological mechanisms of allergic disease, and probiotic immune effects. She has authored over 290 peer reviewed journal articles, invited reviews, and book chapters, and her PhD contributed to a major shift in understanding of allergic disease (first author publication, Lancet 1994). She is actively involved in health policy and has advised government bodies including Food Standards Australia New Zealand. Prof Tang has provided consultant services to the pharmaceutical industry including Astra Zeneca, GSK, Bayer Pharmaceuticals, Pfizer Nutrition, Alphapharm, CSL Bioplasma, Schering Plough, Abbott Nutrition and sat on Industry Medical Advisory Boards and Global Scientific Advisory Committees (Immunology). She is a Board Director of the World Allergy Organisation and sits on expert committees of the American Academy of Allergy Asthma and Immunology (AAAAI), World Allergy Organisation (WAO), and the Australasian Society of Clinical Immunology and Allergy (ASCIA).
Director Regulatory Affairs
Sharon Hanegraaf is an experienced biotech and pharmaceutical professional with over 20 years of experience in the development and registration of therapeutic products. Prior to joining Prota, Sharon was Regulatory Affairs Manager at Hatchtech Pty Ltd who successfully submitted a US NDA and subsequently licensed their lead product. At Acrux Ltd, she was pivotal in the US registration of Axiron®, a novel testosterone replacement therapy. Her depth of experience ranges from early stage drug development, analytical chemistry and manufacturing development and scale-up, quality control and quality assurance, nonclinical and clinical studies as well as numerous FDA interactions.
At Prota Therapeutics, Sharon leads, directs and manages the regulatory strategy within the company, progressing through Phase 3 clinical programs and engaging with regulatory authorities towards filing of Investigational New Drug (IND) and Biologics License Applications (BLAs) in the US.
Director Product Development & Technical Services
Bronwyn Pollock is an experienced biotech and pharmaceutical professional with over 20 years in the industry. Prior to joining Prota as Director Product Development & Technical Services, Bronwyn was Project Manager at Neuren Pharmaceuticals Ltd, a company developing products to treat neurodegenerative diseases. She has also held Senior Management positions in pharmaceutical companies including Hospira Australia (now Pfizer), Acrux Ltd and CSL. Her CMC (Chemistry, Manufacturing and Controls) experience comes from working in R&D, quality and program management, and she has been involved in leading teams in the development and submission of numerous dossiers to EMA, US FDA, Asia and Sth America, technology transfers and launch.
Her key responsibility at Prota is to manage all facets of the drug product development through to Phase 3 clinical trials and regulatory approval.
Dr Aaron Tabensky
Director Clinical Operations & Medical Affairs
Aaron Tabensky has garnered extensive clinical development experience in the pharmaceutical industry over the past 18 years, both in Australia and abroad. Prior to joining Prota, Aaron was based in Singapore where he held positions of Director Clinical Trial Management at Abbott, Assoc. Director Global Program Manager/Regional Therapeutic Area Lead (GI) Asia Pac at Takeda, and Project Management positions at Quintiles. Before that, Aaron held clinical operations roles in Melbourne, Australia with Biogen Idec, PRA International and Servier Laboratories. His experience covers the strategic planning and functional execution of regional and global Phase 1-4 pharmaceutical clinical trials, applying project, program, CRO/vendor, budget and quality management skills and operational insights to the development and successful execution of clinical development plans, while fostering relationships with Key Opinion Leaders and other industry stakeholders. Aaron holds a PhD in the field of Osteoporosis and bone & mineral metabolism.
Aaron’s key responsibilities at Prota are to oversee the successful execution of the clinical development program.